Equities

Nature's Sunshine Products Inc

NATR:NAQ

Nature's Sunshine Products Inc

Actions
Consumer Staples Food Producers
  • Price (USD)15.32
  • Today's Change0.16 / 1.06%
  • Shares traded44.38k
  • 1 Year change+37.03%
  • Beta0.8606
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resells them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

  • Revenue in USD (TTM)447.68m
  • Net income in USD16.54m
  • Incorporated1976
  • Employees814.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Black Diamond Therapeutics Inc0.00-79.79m268.89m54.00--2.41-----1.70-1.700.001.990.00----0.00-57.38-40.29-64.24-43.29------------0.00------9.57---15.37--
Rani Therapeutics Holdings Inc0.00-33.08m277.31m140.00--35.86-----1.29-1.290.000.15340.00----0.00-87.80---140.92-------------28.750.6695-------11.06------
Medifast Inc897.81m67.76m281.52m634.004.151.333.470.31366.206.2082.1519.292.883.37--1,416,106.0021.7141.2532.6269.3873.1573.207.5510.062.25--0.0049.18-32.9416.43-30.7512.255.5917.72
Mersana Therapeutics Inc38.30m-134.81m285.10m123.00--10.19--7.44-1.14-1.140.32030.22870.1549----311,365.80-54.52-61.68-75.37-81.35-----352.01-622.19----0.4749--38.6528.3215.94--9.61--
Nature's Sunshine Products Inc447.68m16.54m286.94m814.0018.071.879.620.6410.84790.847922.968.201.861.9144.39549,974.207.336.5710.669.4172.1972.693.943.741.42--0.01327.725.554.073,965.64--16.73--
Adaptimmune Therapeutics PLC - ADR18.36m-163.41m288.79m449.00--11.84--15.73-0.7285-0.72850.08340.09540.0672--3.6340,886.41-59.85-41.19-78.55-48.21-----890.13-714.26----0.00--122.050.259531.18--0.7202--
CorMedix Inc0.00-50.24m289.75m82.00--4.99-----0.9291-0.92910.001.060.00----0.00-78.96-54.84-88.88-62.32--6.18---18,323.426.41--0.00---100.00---56.02--46.27--
Poseida Therapeutics Inc82.50m-108.86m289.90m335.00--3.42--3.51-1.18-1.180.89070.87390.2864--8.06250,006.10-37.78-40.70-49.17-47.72-----131.94-233.49---12.880.4096---50.42---92.85--19.01--
Revance Therapeutics Inc236.65m-313.72m296.63m534.00------1.25-3.61-3.652.71-0.9450.44821.8710.46---59.42-55.55-69.02-63.2069.11---132.57-304.964.64-30.791.30--76.55128.849.10---0.3022--
Vanda Pharmaceuticals Inc.177.60m-4.89m297.39m203.00--0.5467--1.67-0.0846-0.08463.089.350.273810.325.80874,896.60-0.75386.61-0.88087.6292.4290.55-2.7515.184.69--0.000.00-24.27-0.0496-60.02-36.96-56.77--
Inozyme Pharma Inc0.00-77.11m298.14m59.00--2.51-----1.37-1.370.001.920.00----0.00-48.39-45.00-52.50-48.90------------0.2748-------6.13--2.85--
Emergent Biosolutions Inc1.19bn-565.30m298.69m1.60k--0.4499--0.252-10.87-10.8722.8612.670.49881.996.09740,875.00-23.79-2.94-38.89-3.6641.1953.24-47.69-5.950.55380.06360.5771---6.106.05-259.40---4.29--
ESSA Pharma Inc0.00-27.73m299.45m50.00--2.24-----0.6282-0.62820.003.010.00----0.00-18.71-23.01-19.12-23.67------------0.00------24.27------
XOMA Corp5.81m-45.09m300.16m13.00--3.65--51.65-3.92-3.920.50537.080.0329--1,291.33447,000.00-22.44-4.55-24.19-4.94-----681.69-31.87---24.550.5944---21.06-2.13-105.10--23.16--
Q32 Bio Inc354.00k-83.09m304.52m39.00--6.24--860.24-25.73-25.730.11824.090.002----50,571.43-34.17-34.98-40.05-37.92-----16,901.98-971.76----0.2039---63.97-26.32-2,156.96---60.90--
Data as of May 31 2024. Currency figures normalised to Nature's Sunshine Products Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.